SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-295456
Filing Date
2023-12-14
Accepted
2023-12-14 16:05:52
Documents
12
Period of Report
2023-12-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Document Format Files

Seq Description Document Type Size
1 8-K d523640d8k.htm   iXBRL 8-K 23934
  Complete submission text file 0001193125-23-295456.txt   145870

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA stok-20231212.xsd EX-101.SCH 2881
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE stok-20231212_lab.xml EX-101.LAB 17979
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE stok-20231212_pre.xml EX-101.PRE 11279
6 EXTRACTED XBRL INSTANCE DOCUMENT d523640d8k_htm.xml XML 3341
Mailing Address 45 WIGGINS AVENUE BEDFORD MA 01730
Business Address 45 WIGGINS AVENUE BEDFORD MA 01730 781-430-8200
Stoke Therapeutics, Inc. (Filer) CIK: 0001623526 (see all company filings)

IRS No.: 471144582 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38938 | Film No.: 231487116
SIC: 2834 Pharmaceutical Preparations